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Neurocardiovascular diseases (NCVD) are the leading cause of death in the developed
world and will remain so till 2020. In these diseases the pathologically changed
nervous control of cardiovascular system has the central role. The actual NCV
syndromes are neurogenic hypertension, representing the sympathetically mediated
disorder, and vasovagal syncope, which is the vagally mediated disorders. Vasovagal
syncope, the disease far from its etiological treatment, could benefit from recruiting
and application of antimuscarinic drugs used in other parasympathetic disorders. The
informational spectrum method (ISM), a method widely applied for the characterization
of protein-protein interactions in the field of immunology, endocrinology and anti HIV
drug discovery, was applied for the first time in the analysis of neurogenic hypertension
and vasovagal syncope therapeutic targets. In silico analysis revealed the potential
involvement of apelin in neurogenic hypertension. Applying the EIIP/ISM bioinformatics
concept in investigation of drugs for treatment of vasovagal syncope suggests that
78% of tested antimuscarinic drugs could have anti vasovagal syncope effect. The
presented results confirm that ISM is a promissing method for investigation of molecular
mechanisms underlying pathophysiological proceses of NCV syndromes and discovery
of therapeutics targets for their treatment.
Keywords: in silico analysis, neurocardiovascular diseases, neurogenic hypertension, protein-protein interaction,
vasovagal syncope
INTRODUCTION
NCVD are the syndromes where autonomic nervous system (Zoccoli et al., 2001; Bojic, 2003)
dysfunction plays a dominant etiological role (Goldstain, 2001; Bojic et al., 2012a,b). NCV disorders
can be classified as sympathetically mediated disorders (i.e., neurogenic hypertension, NH) vs.
vagally mediated disorders (i.e., vasovagal syncope, VVS), though in many disorders both systems
are dysfunctional (Goldstain, 2001).
NH is characterized by an increased level of sympathetic nervous activity (SNA) (Fisher
and Paton, 2011). SNA is in reciprocal interaction with the number of important systems for
the pathophysiological profile of NH, like inflammation, angiotension II system and vascular
dysfunction. Recently, due to its potential causal role in the genesis of NH, an emphasis was put
on the role of oxidative stress in brain stem structures.
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Reactive oxygen spices (ROS) in the brain can be generated
in angiotesin II dependent and angiotensin II independent
manners. The most studied mechanism for investigating the
potential causal treatment of NH is Ang 1-7-MAS receptor-NO
mechanism (Zimmerman, 2011). This mechanism counteracts
prohypertensive actions of ROS and represents a good choice
for investigation of therapeutic candidate by Informational
SpectrumMethod (ISM).
In the case of VVS, Nucleus Tractus Solitarii (NTS) in the
brain stem is stimulated either directly (central VVS) or indirectly
(peripheral VVS), provoking an enhancement of vagal tone and
withdrawal of SNA tone. This dual response causes a continuum
of cardiovascular phenotype responses. At the “vagal end” it leads
to the cardioinhibitory type of VVS (bradicardia as a dominant
cause of the VVS), while on the “sympathetic end” causes the
vasodepressor type of VVS (hypotension as a dominant cause of
the VVS). Mixed type of VVS is on themidway between these two
extremes.
The treatment of VVS involves a layered approach with
a combination of lifestyle changes, physical maneuvers,
medications, and implantable devices. The vast majority of
patients with VVS can be adequately controlled with non-
pharmacological approaches and do not require pharmacological
treatment (Raj and Coffin, 2013). There is, however, the minority
of patients with refractory and recurrent VVS who can benefit
from effective pharmacotherapy.
Since the majority of the VVS patients suffer from mixed and
cardioinhibitory type of VVS, we took under consideration the
modulation of vagal tone as the in silico strategy for the new anti
VVS drugs.
The therapy of NH and VVS is far from efficient etiological
treatment. The development of new drugs for treatment of NH
and VVS is time and money consuming process, which can be
accelerated by in silico screening of the molecular libraries for
candidate novel drugs and by repurposing of approved drugs.
FIGURE 1 | Basic steps of ISM method. Sequence→ Transformation of primary protein sequence into sequence of numbers, by assigning of EIIP to each amino
acid→ Numerical presentation→ Discrete Fourier transformation→ Informational spectrum (IS).
The aim of this study was to apply EIIP/ISM approach to
identify candidate neuropeptides and small-molecules for the
potential therapeutics of NH andVVS. The studymay lead to new
insights in the field of neurocardiovascular pharmacotherapy and
pathophysiology.
METHODS
The Long Range Molecular Interactions
Current concepts of intermolecular interactions in biological
systems are based on the surface complementarity between
interacting biomolecules and assumption that the first contact
between interacting molecules is achieved accidentally by the
thermal motions that cause molecular wander. If proteins are
considered as spheres of 18 Å radius (typical of a small
protein), and if spheres associate with every contact, without
regard to orientation, the diffusion-limited association rate
constant, calculated according to Smoluchowski’s equation
(Smoluchowski, 1916) is 7 × 109 M−1s−1. However, before
chemical bond formation takes place, reacting molecular regions
must be positioned close enough (at a distance of ∼2 Å) and
the appropriate atoms must be held in the correct orientation
for the reaction that is to follow, because the attractive forces
involved in the recognition and binding of molecules include all
the weak non-covalent forces. It means that the protein’s binding
site is only a small fraction (∼0.1%) of the surface area. Taking
into account this limitation, the diffusion-limited association
rate constant, predicted from a three-dimensional (3D) “random
diffusion” model and calculated according Smoluchowski’s
equation is∼106 M−1s−1 for a protein-ligand and∼103 M−1s−1
for a protein-protein interaction. Northrup and Erickson have
noted that protein-protein association generally occurs at rates
that are 103–104 times faster than would be expected from simple
considerations of collision frequencies and strict orientation
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effects which assume that productive binding occurs only when
the molecules collide within 2 Å of their final binding site
(Northrup and Erickson, 1992).
Electron-Ion Interaction Potential (EIIP)
In order to overcome the discrepancy between theoretically
estimated values and real values of the associated rate constant
for a intermolecular interactions in biological systems, the long-
range intermolecular interactions (distances between 5 and 1000
A) between interacting molecules was proposed (Veljkovic,
1980). It has been showed that the EIIP and the average
quasivalence numbers (AQVN) Z∗ represent essential molecular
descriptors which determines the long-range properties of
biological molecules (Veljkovic, 1980). These two molecular





i, Type of the chemical element;
FIGURE 2 | Informational spectrum (IS) of (A) MAS1, (B) angiotensin 1-7, (C) apelin 28, and consensus informational-spectrum (CIS) of (D) MAS1 and
angiotensin 1-7 and (E) MAS1 and apelin.
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Z, Valence of the ith chemical element;
n, Number of the ith chemical element atoms in the compound;
m, Number of types of chemical elements in the compond;
N, total number of atoms.
EIIP = 0.25Z∗sin(1.04piZ∗)/2pi (2)
The EIIP values calculated according to the Equation (2) are in
Rydbergs (Ry= 13.6 eV).
Informational Spectrum Method (ISM)
The ISM a virtual spectroscopy method for calculation of the
long-range properties of biological macromolecules, is based on
FIGURE 3 | (A) Consensus informational spectrum (CIS) of primates MAS1; (B) Informational spectrum (IS) of MAS1 of Macaca mulatta; (C) CS of Macaca mulatta
MAS1 and angiotensin 1-7 and (D) CS of Macaca mulatta MAS1 and apelin 28, (E) CS of Macaca mulatta MAS1 and apelin 31 (F) CS of Macaca mulatta MAS1 and
apelin 36.
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a model that assigns to each amino acid a defined parameter
describing a physico-chemical property involved in the biological
activity of the protein and corresponding to electron-ion
interaction potential (EIIP) (Veljkovic et al., 1985).
ISM method consists in three basic steps:
1. Transformation of alphabetic code of primary protein
structure into a sequence of numbers representing EIIP of
each component.
2. Conversion of numerical sequence by fast Fourier
Transformation into information spectrum, which reveals
dominant freqency peaks of the whole organic molecule.
3. Consensus Information Spectrum (CIS) analysis between
information spectrums of two potentially similar or interactive
molecules, which reveales functional locus of the interaction of
two molecules.
Peak frequencies in CIS are common frequency components for
the analyzed sequences. A measure of similarity for each peak
is the signal-to-noise ratio (S/N), the ratio between the signal
intensity at one particular IS frequency and the main value of the
whole spectrum.
Schematic Presentation of ISM is given in Figure 1.
The strong connection between EIIP and Z* molecular
descriptors of small molecules and their biological activities
(carcinogenisity, antibiotic activity, antiviral activity, toxicity,
etc.) has been documented (for review see Veljkovic et al., 2011
and references therein).
The method has been successful in identification of functional
protein domains representing candidate therapeutic targets
for anti-HIV drugs (Veljkovic et al., 2007), anthrax (Doliana
et al., 2008), and human influenza viruses (Veljkovic et al.,
2009a,b; Perovic et al., 2013). It is recognized and used in
more than 100 research centers worldwide (Veljkovic et al.,
2011).
Sequences and Molecular Formulas of
Compounds
Sequences were retrieved from UniProt Database with following
accession numbers: (a) sequences of primates MAS1: Homo
sapiens P04201, Pan troglodytes H2QU00, Macaca mulatta
F7GJU7, Pongo abelii H2PL76GN, Chlorocebus sabaeus
A0A0D9RJ10, Gorilla gorilla gorilla G3R4L5, Papio anubis
A0A096NZT0. (b) sequences of primates Angiotensin 1-7:
Homo sapiens P01019, Pan troglodytes H2Q1B7, Macaca
mulatta G7MFR4, Gorilla gorilla gorilla Q9GLP6. (C) sequences
of primates Apelin: Homo sapiens Q9ULZ1, Macaca mulatta
F7GX01, Gorilla gorilla gorilla G3S9L8, Chlorocebus sabaeus
A0A0D9R7Q2. Sequences are shown inData Sheet 1.
Molecular formulas of compounds: muscarinic modulators
from US Patent 7786308, US Patent 7378447US, and Patent
Application 20100311746A1.
RESULTS
The primary structure of proteins encodes the information
represented by the informational spectrum (IS) frequencies
that correspond to the protein biological function. Mutually
interacting proteins share common information represented by
peaks in their cross-spectrum (Veljkovic et al., 2008). IS of human
MAS receptor (MAS1) is presented on Figure 2A. It contains
characteristic peak at the frequency F(0.240).
MAS1 sequences are highly homologous among primates [see
Supplementary Material: Data Sheet 1 and Exported Multiple
Sequence Alignment (Edgar, 2004) of MAS1 as artwork using
Jalview (Waterhouse et al., 2009; Image 1)]. Informational
spectrum (IS) of MAS1 of Macaca mulatta (Figure 3B) and
consensus informational spectrum (CIS) ofMAS1 of primates are
shown in Figure 3A. It can be seen that information represented
by the CIS frequency F(0.240), is evolutionary conserved among
FIGURE 4 | Schematic presentation of the EIIP/AQVN criterion for selection of candidate antimuscarinic drugs with potential therapeutic effect on
VVS. Active domain (red): AQVN (2.25–2.65), EIIP (0.074–0.096). Chemical space (blue) AQVN (2.40–3.30) EIIP (0.000–0.116) EIIP/AQVN domain of homologous
distribution of >90% compounds from PubChem Compound Database. Statistics: inside the active domain: 21 (78%), outside the active domain: 6 (22%). Asterisk
(*)-position of atropine and propentheline bromide, known anti VVS drugs, within AQVN/EIIP active domain.
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proteins having the same biological function, as it was shown
previously (Glisic et al., 2008).
The sequences of peptides Angiotensin 1-7 and Apelins
of other primates are the same as the sequences of human
peptides (Data Sheet 1) and consequently spectra are the
same.
Figure 2B represents IS of the of humanAngiotensin 1-7 (Ang
1-7). By performing cross-spectral analysis (CS) of MAS receptor
and Ang 1-7 we have identified that these two molecules share
common information corresponding to the IS frequency F(0.057)
(Figure 2D). To confirm the reliability of our findings we have
performed CS analysis of Macaca mulatta MAS1 and Ang 1-
7 and identified the same frequency F(0.057) as dominant and
evolutionary conserved (Figure 3C).
We further apply ISM analyses to identify new peptide
interactors of human MAS1 representing potential candidate
therapeutic agents. To identify peptides which share the common
information represented by the frequency component F(0.057),
270 human peptides of the Human Neuropeptide sequence
database (Kim et al., 2011) were screened by ISM and peptide
apelin 28 (Figure 2C) was found to be among the peptides
with the highest amplitudes and Signal/Noise values at the
frequency F(0.057) in CIS with MAS1 (Figure 2E). Similar results
were obtained for apelin-31 and apelin-36. In further analysis
it was shown that the information represented by CS frequency
for Macaca mulatta MAS receptor and apelins is the same
(Figures 3D–F). According to the IS criterion these peptides are
the potential candidate interactors of MAS1. Presented results
indicate apelin as potential modulator of MAS1 receptor and
novel candidate for treatment of NH.
With respect to the muscarinic antagonists applied in
the therapy of VVS (atropine, propanteline bromide, and
scopolamine), on the basis of AQVN/EIIP analysis we analyzed
the distribution of other muscarinic antagonists which are not
tested for their efficacy in the treatment of VVS (Figures 4, 5).
The analysis revealed that 78% of tested drugs are in the active
AQVN/EIIP domain, implying that there is consistent number
of known antimuscarinic drugs that might have a therapeutic
impact on VVS.
We also analyzed muscarinic receptor modulators from three
patents which are randomly selected among more than 30,000
patents from the patent database (http://www.freepatentsonline.
com), in order test the suitability of the proposed EIIP/AQVN
filter. Results of this analysis are presented in Table 1. As can
FIGURE 5 | The list of antimuscarinic drugs tested for their AQVN/EIIP. Shaded fields- antimuscarinic drugs within the active domain (Figure 3), white
fields-antimuscarinic drugs out of the active domain, bordered fields- antimuscarinic drugs tested for their therapeutical effect on VVS. Probability for the anti VVS
activity of muscarinicdrugs, assessed by EIIP/AQVN criterion, is represented with the gray scale (black-the highest probability, white-the lowest probability).
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be seen, all patented compounds are located within the active
EIIP/AQVN domain (Figure 4).
DISCUSSION
Brain oxidative stress/status defines the state of
sympathoexcitation (increased level of ROS) or
sympathoinhibition (the effect of NO), via angiotensinergic
neurons (Zimmerman, 2011). Since oxidative injury contributes
also to the progressive development of NH, targeting oxidative
stress may represent one of promising therapeutic strategies for
NH treatment.
The ISM analysis identified three forms of apelin as the
potential candidates-interactors of MAS receptor on neurons in
brainstem sympathetic centers and indicated apelin as potential
modulator of MAS1 receptor and novel candidate for treatment
of NH (Figure 6). There is lot of recent evidence of the role
of apelin as therapeutic agent in protection of the brain against
ischemic/reperfusion injury (Yang et al., 2015b), promotion
of neurological function recovery after ischemic brain injury
(Gu et al., 2013) and potential to cure acute and chronic
neurological diseases (Cheng et al., 2012). Synthetic and biased
agonists of apelin have been also developed and latter have
shown in proof-of-concept studies clinical potential (Yang et al.,
2015a). Apelin is adipokine secreted by peripheral tissues but
also present in the hypothalamic neurons, having a major
impact on the genesis and progression of diabetes (Drougard
et al., 2014). This impact is obtained through ROS impact on
sympathetic neuronal centers in the diencephalon which cause
sympathoexcitation and consequently, the liver glycogenolysis
and glusoneogenesis. Our data for the first time point on the
potential role of apelin in the development of NH, again,
through the action of ROS on sympathetic neuronal centers.
Differently from other studies that investigate majorly apelin-
APJ receptor signaling pathway (Chun et al., 2008; Yu et al.,
2014) our analysis points on the novel mechanism, the apelin-
MAS receptor dependent mechanism that could counterbalance
sympathostimulating action of ROS. On the basis of the data
in the literature (Chun et al., 2008; Yu et al., 2014) and on
the basis of our results, there is high probability that apelin
has sympathoinhibiting, anti ROS action also on the brainstem
level. Further in vitro and in vivo studies that would elucidate
the functional significance of apelin-MAS receptor interaction
are needed. This finding could be of importance in designing a
novel therapeutics for NH, but also for better understanding and
treatment of the states like metabolic syndrome, where diabetes,
hypertension, obesity, and obstructive sleep apnea occur in a
cluster (Katsiki et al., 2014).
Muscarinic antagonists that were already tested for their
efficacy in the treatment of VVS were:
1. atropine(i.v.), shown to be fully effective in the cardio-
inhibitory form of tilt-induced vasovagal reflex, but with
limited action in the vasodepressor form (Santini et al.,
1999),
TABLE 1 | EIIP/AQVN values of patented muscarinic modulators: Muscarinic modulators (US Patent 7786308), Muscarinic agonists (US Patent 7378447),
and Modulators of muscarinic receptors (US Patent Application 20100311746A1).
EIIP [RY] AQVN Chemical formula Compound
Patent title: Muscarinic modulators (US Patent 7786308
0.0845 2.590 C23H31FN2O4 ethyl 3-(4-(4-fluorophenyl)(methoxycarbonyl)
amino)piperidin-1-yl)-8-azabicyclo[3.2.1]octane-8-carboxylate
0.0886 2.562 C23H33FN4O3 3-{4-[1-(4-Fluoro-phenyl)-3,3-dimethyl-ureido]-piperidin-1-yl}-8-aza-bicyclo[3.2.1]octane-8-carboxylic
acid ethyl ester
0.0946 2.500 C27H38FN3O3 3-{4-[Cyclohexanecarbonyl-(4-fluoro-phenyl)-amino]-piperidin-1-yl}-8-aza-bicyclo[3.2.1]octane-8-
carboxylic acid ethyl
ester
0.0985 2.444 C23H35N3O2 3-[4-(ethyl-phenyl-amino)-piperidin-1-yl]-8-azabicyclo[3.2.1]octane-8-carboxylic acid ethyl ester
0.0899 2.552 C21H30FN3O3 4-[Acetyl-(4-fluoro-phenyl)-amino]-[1,4′]bipiperidinyl-1′-carboxylic acid ethyl ester
Patent title: Muscarinic agonists (US Patent 7378447)
0.0985 2.618 C19H29N3O4 Carbamic acid tert-butyl ester (R)-(6-(1-(morpholin-4-yl)ethylideneamino)-2(R)-hydroxyindan-1-yl)amide
0.0963 2.431 C22H36BrN3O3 Biphenyl-4-carboxylic acid
(R)-(6-(1-(2-methoxyethyl)methylamino)ethylideneamino)-2(R)-hydroxyindan-1-yl)amide
0.0863 2.579 C31H39N3O3 Biphenyl-1-carboxylic acid
(R)-(6-(1-(2-pentoxyethyl)methylamino)ethylideneamino)-2(R)-hydroxyindan-1-yl)amide
0.0958 2.622 C31H37N3O3 Biphenyl-4-carboxylic acid
(R)-(6-(1-(2-tert-butoxyethyl)methylamino)ethylideneamino)-2(R)-hydroxyindan-1-yl)amide
Patent title: Modulators of muscarinic receptors (US Patent Application 20100311746A1)
0.0758–0.0985 2.390–2.638 1041 compounds
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FIGURE 6 | Proposed mechanism of antagonizing effect of apeline-MAS receptor and Angiotensin II-ATR1 molecular signaling pathways on
preganglionic sympathetic neurons in the brainstem (adapted from Northrup and Erickson 1992.) Ang II, angiotensin II; ATR1, angiotensin 1 receptor; MAS
R, MAS receptor; O2, superoxide; NO, nitric oxide; nNOS, neural nitric oxide synthase; SNA, sympathetic nervous activity; MAP, mean arterial pressure.
2. propantheline bromide (p.o.), shown to be highly effective
in preventing VVS. In addition, propantheline bromide’s
effectiveness is present in the vasodepressor VVS and supports
a role of direct cholinergic control of vascular tone (Yu and
Sung, 1997),
3. scopolamine (t.d.), which showed no effect on VVS (Lee et al.,
1996).
An AQVN/EIIP approach for new candidates in
pharmacotherapy of VVS reveals that on the basis of their
molecular properties, the majority of antimuscarinic drugs (78%
of investigated substances) might have therapeutical potential
for VVS (Figures 4, 5). More, the remaining 22% were out of
AQVN/EIIP active domain, together with scopolamine, the drug
that failed to show anti VVS therapeutical effect (Figure 4).
Best candidates, identified by AQVN/EIIP approach, for future
clinical studies are hydroxysine and cyclopentoate (Figure 5).
The suitability of our method was further confirmed by the
finding that all muscarinic modulators patented in three patents
randomly selected among more than 30,000 patents from
the patent database (http://www.freepatentsonline.com) have
AQVN/EIIP values within AQVN/EIIP active domain (Table 1,
Figure 4).
CONCLUSION
Computer-aided design techniques based on the long-range
intermolecular interactions offer an insight into therapeutical
and pathophysiological aspects of NH and VVS. These
bioinformatics approaches also open a promising path for
molecular investigation of other NCVD and could be of help in
design of in vitro and in vivo animal and clinical studies of these
diseases.
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